Polycyclo Ring System Patents (Class 514/700)
-
Patent number: 9493435Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.Type: GrantFiled: November 1, 2010Date of Patent: November 15, 2016Assignee: MannKing CorporationInventors: Qingping Zeng, Warren S. Wade, John Bruce Patterson
-
Patent number: 9259437Abstract: A scleral lens solution comprising an aqueous mixture that includes sodium, potassium, calcium and magnesium cations and a pH in a range from about 6.5 to about 8.7.Type: GrantFiled: May 22, 2014Date of Patent: February 16, 2016Assignee: SMM Ventures, LLCInventor: Ralph P Stone
-
Patent number: 8945627Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.Type: GrantFiled: May 4, 2012Date of Patent: February 3, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Ho-Chul Shin, Hyunah Cho
-
Publication number: 20140309190Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: June 17, 2014Publication date: October 16, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Publication number: 20140234244Abstract: A floral fragrance composition for use as a replacement for 3-(4-tertbutylphenyl)-2-methylpropanal (LILIAL®) that is a primary perfuming ingredient composition that includes a first perfuming ingredient of (2,5-dimethyl-2,3-dihydro-IH-inden-2-yl) methanol (LILYFLORE®) in an amount of 5 to 25% by weight; a second perfuming ingredient of a dimethyl-5-indanyl propanal compound in an amount of 0.2 to 10% by weight; and one or more secondary perfuming ingredients including at least one of 3-methyl-5-phenylpentanal, decanal, octanal, cuminic aldehyde, cuminic alcohol, carvone, tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, or cis-7-P-menthanol.Type: ApplicationFiled: September 17, 2012Publication date: August 21, 2014Applicant: FIRMENICH SAInventor: Jean-Michel Zenhausern
-
Patent number: 8802659Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: GrantFiled: August 5, 2010Date of Patent: August 12, 2014Assignee: Biogen Idec MA Inc.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Patent number: 8765719Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.Type: GrantFiled: August 20, 2009Date of Patent: July 1, 2014Assignee: Kagoshima UniversityInventors: Masanori Baba, Yuichi Hashimoto
-
Patent number: 8614253Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.Type: GrantFiled: November 8, 2010Date of Patent: December 24, 2013Assignee: MannKind CorporationInventors: John Bruce Patterson, David Gregory Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
-
Patent number: 8455540Abstract: Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof.Type: GrantFiled: December 5, 2008Date of Patent: June 4, 2013Assignee: Universite du Maine (Le Mans)Inventors: Jacques Mortier, Anne-Sophie Castanet, Nguyet Trang Thanh Chau
-
Patent number: 8398759Abstract: An ecologically compatible anti-microbial-adhesion agent is described, which is particularly suitable for use in anti-fouling paints, preferably for boats, characterized in that it comprises a compound selected from eugenol, vanillin, benzaldehyde substituted with one or two substituents selected from the groups —OH (hydroxy) and —OCH3 (methoxy), or any combination thereof. An anti-fouling paint is also described, particularly for boats, comprising the anti-microbial-adhesion agent mentioned above and other components selected from conventional biocides, solvents, resins, pigments, charges and fillings, and combinations thereof.Type: GrantFiled: May 12, 2009Date of Patent: March 19, 2013Assignee: Biopaint S.R.L.Inventors: Cecilia Calisti, Giulio Zanaroli, Fabio Fava, Alessandra Bontempi Di Roccaspada, Maurizio Ruzzi
-
Publication number: 20120321715Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.Type: ApplicationFiled: May 4, 2012Publication date: December 20, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Ho-Chul Shin, Hyunah Cho
-
Publication number: 20120302629Abstract: The present invention provides a biomarker for selecting a patient for treatment with gossypol, wherein the biomarker comprises an elevated expression level of c-Myc, Mcl-1, or combination thereof, relative to the normal expression level of c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for targeting patients for treatment with gossypol, wherein the patient has a disease, condition, or disorder that overexpresses c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for treating or ameliorating a disease, condition, or disorder in a patient comprising determining the expression level of c-Myc, Mcl-1, or combination thereof in the patient and administering gossypol to the patient. In certain embodiments of the invention, the disease is cancer, and the cancer cells show elevated expression levels of c-Myc compared to non-cancerous cells.Type: ApplicationFiled: July 28, 2010Publication date: November 29, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Feng Jiang, Jianting Long, Longchuan Bai
-
Publication number: 20120269901Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.Type: ApplicationFiled: December 19, 2011Publication date: October 25, 2012Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: John C. Reed, Maurizio Pellecchia
-
Publication number: 20120251492Abstract: Provided are a triterpene derivative represented by a general formula (I), a pharmaceutically acceptable salt thereof, and an agent for preventing or treating chronic hepatitis C comprising the triterpene derivative or the salt as an active ingredient: [in the formula (I), R1 represents a carboxyl group, a hydroxymethyl group, —CH2OSO3H, or and R2 represents —OR3 or —O— (CH2) m-OR4, where R3 represents a benzyl group which may be substituted with a hydroxymethyl group, a dimethylaminomethyl group, a phenylaminomethyl group, a morpholinomethyl group, a carboxyl group, or a formyl group, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or a hydroxy C1-6 alkyl group, R4 represents a phenyl group which may be substituted with a carboxyl group, and m represents an integer of 1 to 3, with the proviso that a case where R1 is —CH2OH, and R3 is a C1-6 alkyl group, a C2-6 alkenyl group, or a benzyl group is excluded].Type: ApplicationFiled: December 15, 2010Publication date: October 4, 2012Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Makoto Ishikawa, Shigeki Suzuki, Makoto Aoki, Nobuto Minowa, Kokichi Suzuki
-
Publication number: 20120190649Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: August 5, 2010Publication date: July 26, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Publication number: 20120058172Abstract: Compounds obtainable from plants, e.g. of the genus Eucalyptus, or from microorganisms are shown to be useful as CNS activity modulators useful e.g. in the treatment of depression, for lifting mood and/or for increasing behavioural initiative and the like. This use and related aspects form embodiments of the invention. Also compounds as such are presented. The compounds useful are acylphloroglucine derivatives of the formula I, wherein the substituents are as defined in the description.Type: ApplicationFiled: November 11, 2011Publication date: March 8, 2012Applicant: Intermed Discovery GmbHInventors: Ernst Roemer, Torsten Grothe
-
Patent number: 8039668Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.Type: GrantFiled: April 14, 2010Date of Patent: October 18, 2011Assignee: Burnham Institute for Medical ResearchInventor: Maurizio Pellecchia
-
Publication number: 20110172185Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.Type: ApplicationFiled: August 22, 2009Publication date: July 14, 2011Inventors: Masanori Baba, Yuichi Hashimoto
-
Publication number: 20110144125Abstract: The disclosure describes an animal model for simulating cardiac arrhythmia. Methods of discovering new anti-arrhythmia drugs using the model are described. Novel anti-arrhythmia agents are provided, as are pharmaceutical compositions made from the agents. Methods of inhibiting spontaneous mechanical activity in myocardially-derived biological systems, and methods of treating and preventing cardiac arrhythmia based on novel anti-arrhythmia agents are described. Kits for performing the above methods are also described.Type: ApplicationFiled: August 14, 2009Publication date: June 16, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventor: Paul Wolkowicz
-
Publication number: 20110111057Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.Type: ApplicationFiled: October 7, 2010Publication date: May 12, 2011Inventors: John C. Reed, Maurizio Pellecchia
-
Publication number: 20110091552Abstract: The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.Type: ApplicationFiled: December 27, 2010Publication date: April 21, 2011Inventors: Tim McCaffrey, Dmitry Gagarin, Zhaoqing Yang
-
Publication number: 20110021613Abstract: Compounds obtainable from plants, e.g. of the genus Eucalyptus, or from microorganisms are shown to be useful as CNS activity modulators useful e.g. in the treatment of depression, for lifting mood and/or for increasing behavioural initiative and the like. This use and related aspects form embodiments of the invention. Also compounds as such are presented. The compounds useful are acylphloroglucine derivatives of the formula I, wherein the substituents are as defined in the description.Type: ApplicationFiled: December 11, 2007Publication date: January 27, 2011Applicant: INTERMED DISCOVERY GMBHInventors: Ernst Roemer, Torsten Grothe
-
Publication number: 20100331398Abstract: Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof.Type: ApplicationFiled: December 5, 2008Publication date: December 30, 2010Applicant: UNIVERSITE DU MAINE (LE MANS)Inventors: Jacques Mortier, Anne-Sophie Castanet, Nguyet Trang Thanh Chau
-
Patent number: 7858611Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.Type: GrantFiled: May 9, 2007Date of Patent: December 28, 2010Assignee: BrainCells Inc.Inventors: Carrolee Barlow, Todd A. Carter, Kai Treuner, Kym I. Lorrain
-
Patent number: 7858666Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.Type: GrantFiled: June 9, 2008Date of Patent: December 28, 2010Assignee: MannKind CorporationInventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
-
Patent number: 7851510Abstract: The present invention relates to compounds of general formula (1): in which, independently of each other, R1 and R2 represent: —OH, or —CH2—O—R3, or —CH2—S—R3, or R3, R4, R5 and R6 representing, independently of each other, —H or a carbon-containing group with 1 to 10 carbon atoms, saturated or unsaturated, optionally substituted with one or more heteroatomic groups. The invention also relates to pharmaceutical compositions containing these compounds, and their uses, in particular in the context of the treatment of cancer.Type: GrantFiled: January 6, 2005Date of Patent: December 14, 2010Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Institut National de la Sante et de la Recherche Medicale (I.N.S.E.R.M)Inventors: Vi-Thuy Dao, Jean De Gunzburg, Robert Michelot, Oliver Christophe De Mil
-
Publication number: 20100286284Abstract: The present invention relates to new compounds of formula (I) and to their use as medicaments. Preferably, the said compounds are used in the preparation of a medicament or food supplement intended for the treatment and/or prevention of ailments or pathologies ensuing from a disorder of the reuptake of the following neurotransmitters: dopamine, serotonin and/or noradrenaline.Type: ApplicationFiled: January 13, 2009Publication date: November 11, 2010Applicant: Pierre Fabre MedicamentInventors: Christel Fiorini-Puybaret, Philippe Joulia
-
Patent number: 7825104Abstract: Phenylboronic acid and water soluble derivatives thereof and related boronic acid compounds are used for treating fungal and bacterial infections.Type: GrantFiled: July 23, 2002Date of Patent: November 2, 2010Assignee: Ramot at Tel Aviv University Ltd.Inventors: Amihay Freeman, Rina Segal, Yael Dror
-
Publication number: 20100267781Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.Type: ApplicationFiled: April 14, 2010Publication date: October 21, 2010Applicant: Burnham Institute for Medical ResearchInventor: Maurizio Pellechia
-
Publication number: 20100189683Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
-
Publication number: 20090324754Abstract: The present invention relates to the use of a Eucalyptus for preparation of a drug or a dietary supplement intended for treatment and/or prevention of affections or pathologies caused by neuromediator recapture disorder. The present invention also relates to a new enriched extract of Eucalyptus characterized in that it contains at least one compound having the formula (I) or any one of its diastereoisomers in which R1 forms a C?CH2 substituent with the carbon to which it is joined, a formula (II) substituent and R2 which represents an isobutyl, ?-isobutyl or ?-isobutyl substituent; and the method of preparation thereof.Type: ApplicationFiled: July 27, 2007Publication date: December 31, 2009Applicant: Pierre Fabre MedicamentInventors: Christel Fiorini-Puybaret, Bernard Fabre, Cécile Chauvin, Philippe Joulia
-
Publication number: 20090238785Abstract: A compound comprising a Schiffs base of an aldehydic musk aromachemical with a substantially nonvolatile, odorless amine, wherein the imine moiety of said Schiffs base compound is stable against oxidation to a carboxyl group or a mixture of said compounds; said Schiffs base compound being biodegradable over time to said aldehydic musk and said nonvolatile, odorless amine; as well as compositions, products, preparations or articles having improved aroma, fragrance or odor characteristics containing as active ingredient such compound or mixture of compounds; the aldehydic musks themselves, and methods for the preparation of the Schiff bases and methods of imparting fragrance characteristics to substrates.Type: ApplicationFiled: June 24, 2005Publication date: September 24, 2009Applicant: Flexitral, Inc.Inventor: Luca Turin
-
Publication number: 20090082424Abstract: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-XL, and the like). The present invention also provides compositions comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents). The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases) comprising administering a composition comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents) and/or techniques (e.g.Type: ApplicationFiled: September 30, 2008Publication date: March 26, 2009Inventors: Shaomeng Wang, Dajun Yang, Liang Xu
-
Publication number: 20090076136Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, each comprising as an effective ingredient at least one compound selected from the group consisting of specified compounds having an insulin-mimetic action, derivatives thereof, and pharmacologically acceptable salts thereof.Type: ApplicationFiled: November 3, 2008Publication date: March 19, 2009Inventors: Tatsuji ENOKI, Eiji Kobayashi, Kinuko Ogawa, Yoko Kudo, Masashige Tanabe, Hiromu Ohnogi, Hiroaki Sagawa, Ikunoshin Kato
-
Publication number: 20090062384Abstract: The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effective ingredient. T. nucifera extracts or abietane diterpenoid compound or terpenoid compound isolated from the same of the present invention not only shows excel lent anti-oxidative activity to LDL but also effectively inhibits ACAT activity. Further, T. nucifera extracts of the present invention reduce blood LDL cholesterol and total cholesterol. Therefore, the composition of the present invention can be effectively used for the prevention and the treatment of cardiovascular diseases including hyperlipidemia and atherosclerosis caused by the LDL oxidation and the synthesis and accumulation of cholesteryl ester.Type: ApplicationFiled: November 5, 2008Publication date: March 5, 2009Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Tae-Sook Jeong, Woo-Song Lee, Hyoung-Chin Kim, Yang-Kyu Choi, Ju-Ryoung Kim, So-Jin An, Kyoung-Ran Im, Ki-Chang Jang, Og-Sung Moon, Jun-Seock Son
-
Publication number: 20090030088Abstract: 6-methoxy gossypol and 6,6?-dimethoxy gossypol were isolated from cottonseeds. Bioactivities of these two gossypol derivatives and gossypol were investigated regarding their antioxidant activities, DNA damage prevention ability, anti-cancer, and anti-trypanosomal activities. Both methoxy compounds had nearly equivalent bioactivities, but gossypol showed greater bioactivities than either methoxy derivative on free radical scavenging activity, reducing power, and DNA damage prevention ability. Gossypol and its methoxy derivatives inhibited growth of three cancer cell lines, i.e., SiHa (cervical cancer), MCF-7 (breast cancer) and Caco-2 (colon cancer) cells, in a dose dependent manner. These three compounds also significantly inhibited growth of trypanosome T. brucei, the cause of African Sleeping Sickness, which affects thousands in western and central Africa.Type: ApplicationFiled: April 21, 2008Publication date: January 29, 2009Applicant: Clemson UniversityInventors: Xi Wang, James C. Morris, Feng Chen, Thomas Beckham
-
Publication number: 20090010878Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: June 2, 2008Publication date: January 8, 2009Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
-
Patent number: 7470821Abstract: The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two carbon atoms adjacent to the same aromatic chain, i.e., the first aromatic chain, and R is a phosphate group or a phosphate group mimetic linked to a carbon atom of the second aromatic chain.Type: GrantFiled: June 29, 2004Date of Patent: December 30, 2008Assignees: Valorisation-Recherche, Limited Partnership, Universite Paul Sabatier Toulouse IIIInventors: Chantal Dax, Casimir Blonski, Laurent Azema, Jurgen Sygusch
-
Patent number: 7432300Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.Type: GrantFiled: June 15, 2007Date of Patent: October 7, 2008Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Jiangyong Chen
-
Patent number: 7342046Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.Type: GrantFiled: March 24, 2005Date of Patent: March 11, 2008Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Jiangyong Chen
-
Patent number: 7101907Abstract: The topical administration of statins for the treatment of bone disorders is disclosed.Type: GrantFiled: August 29, 2003Date of Patent: September 5, 2006Assignees: ZymoGenetics Corporation, OsteoScreen IP, LLCInventors: Shirley R. Gasper, Robert R. West, Theresa Martinez, Kirk G. Robbins, Patricia A. McKernan, Nand Baindur, Virender M. Labroo, Gregory R. Mundy
-
Patent number: 7067524Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 18, 2004Date of Patent: June 27, 2006Assignee: WyethInventors: Richard E. Mewshaw, Richard J. Edsall, Cuijian Yang, Heather A. Harris, James C. Keith, Jr., Leo M. Albert, Eric S. Manas
-
Patent number: 6914074Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 11, 2002Date of Patent: July 5, 2005Assignee: WyethInventors: Richard E. Mewshaw, Richard J. Edsall, Cuijian Yang, Heather A. Harris, James C. Keith, Jr., Leo M. Albert, Eric S. Manas
-
Publication number: 20040266865Abstract: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.Type: ApplicationFiled: April 16, 2004Publication date: December 30, 2004Inventors: Raymond Andersen, David E. Williams, Alice Mui, Christopher Ong, Gerald Krystal
-
Publication number: 20040214902Abstract: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-XL, and the like). The present invention also provides compositions comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents). The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases) comprising administering a composition comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents) and/or techniques (e.g.Type: ApplicationFiled: December 5, 2003Publication date: October 28, 2004Applicants: The Regents of the University of Michigan, Georgetown UniversityInventors: Shaomeng Wang, Dajun Yang
-
Patent number: 6794415Abstract: A method of treating osteoporosis in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount to treat osteoporosis of a compound selected from the group consisting of a compound of the formula: wherein the substituents are defined as in the Specification.Type: GrantFiled: July 8, 2002Date of Patent: September 21, 2004Assignee: Aventis Pharma S.A.Inventors: Dominique Lesuisse, Jean-Georges Teutsch
-
Patent number: 6773727Abstract: Low concentrations of gossypol and related phyllophage toxins from cotton improve the effectiveness of insecticidal agents against social insects, including cockroaches, and particularly termites and ants. Levels of gossypol and other cotton phyllophage toxins which are sufficiently low as to be non-biocidal to social insects alone, will significantly increase the control efficacy of other insecticidal agents. Consequently, use of these low levels of these cotton phyllophage toxins allows the levels of insecticidal agents necessary for effectively controlling the insects to be significantly reduced relative to applications without cotton phyllophage toxins. Furthermore, insecticidal agents which are normally ineffective for control of social insects when used alone, may be effective when used in conjunction with the cotton phyllophage toxins.Type: GrantFiled: August 13, 2001Date of Patent: August 10, 2004Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Maria G. Rojas, Juan A. Morales-Ramos, Peter J. Wan
-
Patent number: 6608107Abstract: This invention also provides a method to inhibit neovascularization in tissue by delivering to the cell or tissue an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Also provided herein is a method for treating a disease associated with hyproliferation of endothelial cells and/or neovascularization by administering to a subject an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Kits to treat patients are provided as well.Type: GrantFiled: December 14, 2001Date of Patent: August 19, 2003Assignee: Wackvom LimitedInventors: Kin-Ping Wong, Ming-Chung Wong
-
Patent number: 6593364Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (I) or a salt thereof: wherein R1 represents a hydroxyl group, arylmethyloxy, lower alkoxy, or lower alkanoyloxy, R2 represents lower alkyl, lower alkenyl, —CH2OR5, formyl, —COOR6, or —CH2N(R7)R8, or R1 and R2 may combine with each other to form —O—C(R9)R10—O—CH2—, R3 and R4, which may be the same or different represent a hydrogen atom, a hydroxyl group, lower alkyl, lower alkenyl, aryl, hydroxymethyl, —N(R11)R12, formyl, —COOR6, or —OR13, or R3 and R4 may combine with each other to form oxo, hydroxyimino, or alkylidene and X represents O, CH2, or NH.Type: GrantFiled: August 6, 2001Date of Patent: July 15, 2003Assignee: Meiji Seika Kaisha, Ltd.Inventors: Kazue Sasaki, Nobuto Minowa, Shoji Nishiyama, Hiroyuki Kuzuhara
-
Patent number: RE40862Abstract: A method for treating cancer in a human, which comprises administering to the human subject an anti-cancer effective amount of a compound selected from gossypol, gossypol acetic acid, gossypolone, metabolites thereof, or physiologically acceptable salts thereof. Also included is a method for treating cancer in a human which comprises administering to the human subject an anti-cancer effective amount of any of the compounds listed above in combination with an anti-cancer effective amount of other conventional chemotherapeutic agents. Finally, the invention also encompasses a pharmaceutical composition comprising an anti-cancer effective amount of gossypol, gossypol acetic acid, or gossypolone, and an anti-cancer effective amount of a conventional chemotherapeutic agent, or combinations of the latter.Type: GrantFiled: October 16, 2006Date of Patent: July 21, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Mary R. Flack, Richard Knazek, Marcus Reidenberg